Halibrell (Ranolazine)

Halibrell is indicated for the management of chronic stable angina, a condition characterized by chest pain due to reduced blood flow to the heart muscle.

• Reduces frequency of angina episodes in patients already receiving optimal therapy.
• Improves exercise tolerance and time to onset of chest pain.
• May be used as add‑on therapy when beta‑blockers, calcium channel blockers, or nitrates are insufficient.
• Provides symptomatic relief without affecting heart rate or blood pressure significantly.
• Can be considered in patients who cannot tolerate other anti‑anginal agents.

Side effects reported with ranolazine, the active component of Halibrell, vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Dizziness or a light‑headed feeling, especially when standing up quickly.
• Nausea, vomiting, or abdominal discomfort that may be mild to moderate.
• Constipation or diarrhea, sometimes alternating during treatment.
• Headache of varying intensity, often transient.
• Mild fatigue or a general feeling of tiredness.
• Dry mouth or altered taste sensation that can affect eating.
• Tremor or shakiness, usually mild and temporary.

Serious

• Prolonged QT interval on electrocardiogram, which can increase the risk of cardiac arrhythmias.
• Severe allergic reactions such as rash, itching, swelling of the face, lips, or tongue, and possible anaphylaxis.
• Pulmonary edema or shortness of breath indicating fluid accumulation in the lungs.
• Significant elevations in liver enzymes, suggesting possible hepatic injury that may require monitoring.

When prescribing Halibrell, clinicians consider several precautions to ensure safe use and to minimize potential risks associated with ranolazine therapy.

• Assess baseline electrocardiogram for QT interval prolongation before initiating therapy.
• Use caution in patients with hepatic impairment, as ranolazine is metabolized by the liver.
• Monitor renal function; dose adjustments may be needed in severe renal insufficiency.
• Avoid concomitant use with strong CYP3A inhibitors that can increase ranolazine plasma levels.
• Counsel patients to report any new palpitations, dizziness, or visual disturbances promptly.
• Consider drug interactions in patients taking antiarrhythmic agents or other QT‑prolonging medications.

Ranolazine can interact with several medications, affecting its concentration or cardiac electrophysiology. Understanding these interactions helps clinicians manage therapy safely.

Avoid

• Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or HIV protease inhibitors.
• Other QT‑prolonging agents, including certain antiarrhythmics (e.g., sotalol) and some antipsychotics.
• Medications that significantly raise serum potassium levels, which may exacerbate cardiac effects.

Use with caution

• Moderate CYP3A4 inhibitors like diltiazem or verapamil; dose may need adjustment.
• Drugs that are substrates of CYP2D6, as ranolazine can inhibit this pathway.
• Anticoagulants such as warfarin, where monitoring of INR may be required.
• Diuretics that affect electrolyte balance, requiring periodic laboratory checks.